Why the study?
Early diagnosis of Fabry disease is required to initiate etiological treatment and prevent irreversible organ damage, but identification can be challenging.
This case highlights the importance of correct phenotyping and genetic evaluation for the diagnosis of Fabry disease, even in patients with pre-existing congenital heart defects.
Early FD diagnosis via red flags, enzyme assay, and GLA sequencing may aid management; leaves open optimal cardiogenetic screening protocols.
Fabry disease (FD) is a multiorgan disease, which can potentially affect any organ or tissue, with the heart, kidneys, and central nervous system representing the major disease targets. FD can be suspected based on the presence of specific red flags, and the subsequent evaluation of the α-Gal A activity and GLA sequencing, are required to confirm the diagnosis, to evaluate the presence of amenable GLA mutation, and to perform a cascade program screening in family members. An early diagnosis is required to start an etiological treatment and to prevent irreversible organ damage. Here, we describe a case of a 37-years-old patient, with a surgically repaired congenital heart defect in his childhood, who had a late diagnosis of FD based on the clinical history and targeted genetic evaluation. This case highlights the importance to perform a correct phenotyping and definite diagnosis of FD, to start an early and appropriate treatment in the index patient, and a cascade clinical and genetic screening to identify other family members at risk, which may benefit from specific treatment and/or a close follow-up.
No takes yet. Share an insight, caveat, or question.
Rubino et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: